Results from innovative tuberculosis vaccine trial show potential for new BCG revaccination strategies and hope for subunit vaccines.

In a prevention-of-infection phase 2 trial conducted in Worcester and Cape Town, South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents.  An experimental vaccine candidate, H4:IC31, also appeared to reduce sustained infections, although not at statistically significant levels. However, the trend observed for H4:IC31 is the first time a subunit vaccine has shown any indication of ability to protect against TB infection or disease in humans.

Joint SATVI/DTHF press release. Click here.

Aeras press release. Click here.

Study fact sheet. Click here.